Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo’s Deal With Ranbaxy Hits A Snag

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - There is trouble for Japanese drug maker Daiichi Sankyo's takeover proposal of India's largest pharmaceutical company Ranbaxy as India's stock market regulator, the Securities and Exchange Board of India, has rejected a plea from Ranbaxy promoters to execute the 34.8 percent stake sale to Daiichi Sankyo through live-market transactions

You may also be interested in...



2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

Ranbaxy Officially Becomes A Daiichi Subsidiary As Management Turns To Business Synergies

MUMBAI - Daiichi Sankyo has acquired 52.5 percent of Ranbaxy's equity share capital for $736 million. Ranbaxy announced that the committee of the board of directors of Ranbaxy approved Oct. 20 the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo. With this Ranbaxy has officially become a subsidiary of Daiichi Sankyo

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel